Roche

Overview

Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland, with significant neuroscience R&D programs. [@roche]
[1] [@gantenerumab]

Company Overview

| Attribute | Value | [@rochea]
|-----------|-------|
| Ticker | SIX: RO, OTC: RHHBY |
| Founded | 1896 |
| Headquarters | Basel, Switzerland |
| CEO | Thomas Schinecker |
| Market Cap | ~\$260B (2026) |

[Alzheimer's Disease](/diseases/alzheimers-disease) Programs

Gantenerumab (Trontinemab)

• Mechanism: Monoclonal antibody targeting amyloid plaques
• Target: [Aβ](/proteins/amyloid-beta) fibrils and plaques
• Status: Withdrawn from FDA review (2024)
• Trial: GRADUATE I & II Phase 3
• Note: Showed amyloid removal but insufficient clinical efficacy

Crenezumab (Mab 114)

• Mechanism: Monoclonal antibody targeting Aβ monomers and oligomers
• Target: Aβ oligomers
• Status: Failed Phase 3 (CREAD)
• Trial: CREAD Phase 3 (terminated for futility)

Trontinemab (RO7129511)

• Mechanism: Brain-penetrant anti-Aβ antibody
• Target: Amyloid plaques
• Status: Phase 2

[Parkinson's Disease](/diseases/parkinsons-disease) Programs

Ricobendazole

• Mechanism: [α-Synuclein](/proteins/alpha-synuclein) aggregation inhibitor
• Target: α-Synuclein
• Status: Phase 1

Other PD Programs

• Anti-α-Syn antibody — Discovery stage

[Multiple System Atrophy](/diseases/multiple-system-atrophy) Programs

...

Overview

Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland, with significant neuroscience R&D programs. [@roche]
[1] [@gantenerumab]

Company Overview

| Attribute | Value | [@rochea]
|-----------|-------|
| Ticker | SIX: RO, OTC: RHHBY |
| Founded | 1896 |
| Headquarters | Basel, Switzerland |
| CEO | Thomas Schinecker |
| Market Cap | ~\$260B (2026) |

[Alzheimer's Disease](/diseases/alzheimers-disease) Programs

Gantenerumab (Trontinemab)

• Mechanism: Monoclonal antibody targeting amyloid plaques
• Target: [Aβ](/proteins/amyloid-beta) fibrils and plaques
• Status: Withdrawn from FDA review (2024)
• Trial: GRADUATE I & II Phase 3
• Note: Showed amyloid removal but insufficient clinical efficacy

Crenezumab (Mab 114)

• Mechanism: Monoclonal antibody targeting Aβ monomers and oligomers
• Target: Aβ oligomers
• Status: Failed Phase 3 (CREAD)
• Trial: CREAD Phase 3 (terminated for futility)

Trontinemab (RO7129511)

• Mechanism: Brain-penetrant anti-Aβ antibody
• Target: Amyloid plaques
• Status: Phase 2

[Parkinson's Disease](/diseases/parkinsons-disease) Programs

Ricobendazole

• Mechanism: [α-Synuclein](/proteins/alpha-synuclein) aggregation inhibitor
• Target: α-Synuclein
• Status: Phase 1

Other PD Programs

• Anti-α-Syn antibody — Discovery stage

[Multiple System Atrophy](/diseases/multiple-system-atrophy) Programs

Cinumercept (RG6102)

• Mechanism: Anti-α-synuclein monoclonal antibody
• Target: [Alpha-synuclein](/proteins/alpha-synuclein) pathology
• Status: Phase 2 (AMBAR study)
• Indication: Multiple System Atrophy
• Note: Results from AMBAR study published in Lancet Neurology 2025 showing efficacy [@poewe2025]
• Partnership: Developed with Genentech

Financial Highlights

| Year | Revenue | Key Products |
|------|---------|---------------|
| 2025 | CHF 68B | Ocrevus, Hemlibra, Tecentriq |
| 2024 | CHF 62B | Ocrevus, Hemlibra, Avastin |

Funding

• IPO: 2000 (SIX: RO)
• Market Cap: ~$260B (2026)
• 2025 Revenue: CHF 68B (~5B)
• 2024 Revenue: CHF 62B
• R&D Investment: ~$15B annually
• Dividend: CHF 2.70 per share (2025)

Partnerships

• Genentech: US commercialization (subsidiary)
• AC Immune: [Tau](/proteins/tau) and α-Syn programs

[Neurodevelopmental Epilepsy Programs]

SCN1A AAV Gene Therapy — Dravet Syndrome (Partnered with Neurocrine)

Roche, in partnership with [Neurocrine Biosciences](/companies/neurocrine-biosciences), is developing an AAV-based gene therapy for [Dravet syndrome](/diseases/dravet-syndrome) caused by loss-of-function variants in [SCN1A](/entities/scn1a).

• Mechanism: AAV-delivered full-length SCN1A gene replacement
• Target: [SCN1A](/entities/scn1a) (Nav1.1 sodium channel, ~6 kb coding sequence)
• Technical approach: Addressing the AAV packaging constraint through optimized construct design
• Stage: IND-enabling (March 2026)
• Partner: [Neurocrine Biosciences](/companies/neurocrine-biosciences) (NASDAQ: NBIX)

Competitive landscape: The program competes with [Stoke Therapeutics](/companies/stoke-therapeutics) ASO (STK-001, Phase 2) and [Encoded Therapeutics](/companies/encoded-therapeutics) AAV CRISPRa (ETX101, Phase 1).

KCNQ2/3 Channel Opener (Partnered with Neurocrine)

Roche and Neurocrine are also developing a KCNQ2/KCNQ3 potassium channel opener program for focal onset seizures.

• Mechanism: Enhances M-current (Kv7.2/Kv7.3 channels) to stabilize neuronal excitability
• Stage: Phase 1

Related Pages

• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [PD Pipeline Companies](/companies/pd-pipeline-companies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dravet Syndrome](/diseases/dravet-syndrome)
• [Neurocrine Biosciences](/companies/neurocrine-biosciences)
• [Stoke Therapeutics](/companies/stoke-therapeutics)
• [Encoded Therapeutics](/companies/encoded-therapeutics)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Alzheimer's drug development
• [Parkinson's Disease](/diseases/parkinsons-disease) — Parkinson's drug development
• [Multiple System Atrophy](/diseases/multiple-system-atrophy) — MSA research
• [MSA Treatment](/therapeutics/multiple-system-atrophy-msa-treatment) — Treatment pipeline
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade) — Amyloid-targeting therapies
• [Tau Pathology](/proteins/tau) — Tau-targeting therapies
• [Clinical Trials Overview](/entities/clinical-trials) — Clinical trial portfolio

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Related Companies

• [Biogen](/companies/biogen)
• [Acumen Pharmaceuticals](/companies/acumen-pharmaceuticals)
• [Inmune Bio](/companies/inmune-bio)
• [Annovis Bio](/companies/annovis-bio) - Competitor in AD space (Leqembi, Aduhelm)
• [Eli Lilly](/companies/eli-lilly) - Competitor in AD space (Kisunla)
• [Eisai](/companies/eisai) - Partner for gantenerumab
• [Denali Therapeutics](/companies/denali) - Neurodegeneration pipeline
• [Prothena](/companies/prothena) - Collaboration partner
• [AC Immune](/companies/ac-immune) - Tau programs
• [Vaxxinity](/companies/vaxxinity) - AD vaccine pipeline

Neuroscience Pipeline

Roche has a significant investment in neuroscience research, with multiple programs in clinical development for [Alzheimer's disease](/diseases/alzheimers-disease), Parkinson's disease, and other neurological disorders.

Alzheimer's Disease

Crenezumab (MABT5102A)
Anti-amyloid beta monoclonal antibody[@roche].

• Phase II ACCORD: Results showed reduced amyloid but not clinical benefit
• Partnership: Genentech (Roche subsidiary)

Anti-tau antibodies: Multiple programs in various stages

SOD1 inhibitors: For ALS (in partnership)

Parkinson's Disease

• [GBA](/entities/gba) program: Gene therapy approaches
• [LRRK2](/entities/lrrk2) inhibitors: Early discovery
• Alpha-synuclein aggregation inhibitors: Preclinical

Multiple Sclerosis

Ocrelizumab (Ocrevus): CD20 antibody for MS

• Approved: 2017 for relapsing and primary progressive MS
• Mechanism: B-cell depletion
• Market: >B annually

Spinal Muscular Atrophy

Evrysdi (risdiplam): SMN2 splicing modifier

• Approved: 2020 for SMA
• First oral treatment for SMA
• Partnership: PTC Therapeutics (Roche has rights)

Diagnostics Division

Roche's diagnostics business is a key differentiator:

• Cerebral spinal fluid (CSF) biomarkers: p-tau, Aβ42
• Blood-based biomarkers: p-Tau181, [p-Tau217](/biomarkers/p-tau-217)
• Neuroimaging AI: Partnership for amyloid PET analysis

Financial Overview

• Founded: 1896
• Headquarters: Basel, Switzerland
• SIX Swiss Exchange: ROG
• Market Cap: ~80B (as of 2026)
• 2025 Revenue: ~8B (pharmaceuticals + diagnostics)

Key Products

• MabThera/Rituxan: Anti-CD20, cancer and autoimmune
• Avastin: Anti-VEGF, cancer
• Herceptin: Anti-HER2, breast cancer
• Hemlibra: Factor VIII mimetic, hemophilia A

Research Partnerships

• AC Immune: Tau and amyloid partnerships
• Prothelia: Muscular dystrophy
• GeNeuro: MS partnerships
• Academic collaborations: Multiple university partnerships worldwide

[@roche]: [Roche Neuroscience](https://www.roche.com/). Roche Holding AG.

References

Unknown, Roche Corporate Website (n.d.)

Unknown, Gantenerumab GRADUATE Results (n.d.)

Unknown, Roche Neuroscience Pipeline (n.d.)

Pathway Diagram

The following diagram shows the key molecular relationships involving Roche discovered through SciDEX knowledge graph analysis: